Grifols, ES0171996087

Grifols stock falls 3.09 percent to EUR 9.36 on BME

Published on 09/26/2026 at 11:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

H1 net profit rose 28.7 percent to EUR 227 million through June 30, 2026. Reuters reported on September 24, 2026, that a Winnipeg license was suspended.

Fotorealistische Plasma-Fraktionierungsanlage, Biotech-Produktion, unbeschriftete Industriehalle — Fotorealistische Ansicht einer Plasma-Fraktionierungsanlage zeigt Grifols S.A. ES0171996087 in moderner Biotech-Produktion mit Reinraumtechnik, Illustration mit AI erstellt.

Grifols stock (ISIN ES0171996087) fell 3.09 percent to EUR 9.36 at the BME close on September 23, 2026, putting the share price against a fresh regulatory issue in its plasma network. As Reuters reported on September 24, 2026, Health Canada suspended the license of Grifols' Taylor Avenue facility in Winnipeg, while the company said operations would be unaffected.

Canada license raises operational questions

The Winnipeg facility had already paused plasma collection, according to Reuters. Grifols said it was working with the regulator on a reopening plan after an inspection, making quality controls and the timing of renewed collections important operating milestones.

The regulatory action follows concerns about the site's quality management system. For shareholders, the immediate issue is less the paused site itself than the speed at which Grifols can restore collection capacity while maintaining its broader plasma supply system.

H1 profit growth sets the counterweight

Operational progress was visible in the first-half numbers. In its investor update dated July 28, 2026, Grifols reported revenue of EUR 3.6 billion through June 30, 2026, up 2.6 percent at constant currency, while net profit rose 28.7 percent to EUR 227 million.

The company also reported first-half adjusted EBITDA of EUR 854 million, up 2.4 percent year over year, and free cash flow before mergers and acquisitions of EUR 91 million. That combination gives the stock a measurable earnings counterweight to the Canadian compliance problem, although the share price still sits below the EUR 10 level.

Analysts keep a cautious split

The U.S. ADR provides a separate view of sentiment. MarketBeat reported on September 19, 2026, that Wall Street Zen upgraded Grifols from hold to buy, while the broader consensus remained Reduce with an average target of USD 10.00.

The contrast is clear: first-half profit growth supports the recovery case, while plasma-site oversight remains a concrete execution risk. The next market signal will be whether investors place more weight on cash generation or on the timetable for restoring collection operations.

BME close stays under pressure

Grifols stock stood at EUR 9.36 on BME at the official close of September 23, 2026, down 3.09 percent on the session. The price move gives the regulatory headline immediate market relevance, while the EUR 227 million first-half profit provides the key quantified comparison for the company's operating performance.